Scholarlink

<p>In this phase 3 trial, penpulimab combined with chemotherapy was assessed against a regimen of placebo plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). 291 patients were randomised and allocated in a 1:1 ratio in order to receive penpulimab (<i>n</i> = 144; 200 mg) or placebo (<i>n</i> = 147; 200 mg), plus chemotherapy (cisplatin/carboplatin and gemcitabine) every 3 weeks. Patients followed by maintenance therapy with penpulimab or placebo after 6 cycles. The primary endpoint of this study was progression-free survival (PFS) according to RECIST v1.1, and a significantly longer median PFS in the penpulimab arm versus the placebo arm (9.63 versus 7.00 months; hazard ratio 0.45, 95% CI: 0.33–0.62, <i>P</i> &lt; 0.0001) was demonstrated in this prespecified interim analysis. The key secondary endpoint was the overall survival (OS). However, the OS data were still immature, and the median OS was not achieved (hazard ratio, 0.94; 95% CI: 0.63–1.40). The occurrence of treatment-related adverse events (grade ≥ 3) was 89.0% and 85.9% in two arms, with the most common being reduced the quantity of neutrophil (56.2% vs. 62.0%), reduced the quantity of white blood cell (54.1% vs. 54.9%), and anemia (45.2% vs. 38.7%). In the penpulimab arm, 6 patients (4.1%) experienced immune-related adverse events (grade ≥ 3). Adding penpulimab to chemotherapy led to a notable enhancement in PFS for the first-line R/M NPC treatment, alongside a safety profile that was both manageable and tolerable. ClinicalTrials.gov identifier NCT04974398.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月8日

查看全文
  • Shuang Huang,
  • Feng Liu,
  • Song Qu,
  • Lisha Chen,
  • Ping Zhou,
  • Shenhong Qu,
  • Xiaohong Ai,
  • Yong Chen,
  • Meilian Liu,
  • Rensheng Wang,
  • Kelvin KW Chan,
  • Peng Zhang,
  • Chunhong Hu,
  • Jiyu Wen,
  • Jian Zhang,
  • Qin Lin,
  • Xiaojiang Li,
  • Kangsheng Gu,
  • Li Xiang,
  • Dongxia Wang,
  • Jingao Li,
  • Daren Lin,
  • Desheng Hu,
  • Jianwu Ding,
  • Siyang Wang,
  • Xiaoming Huang,
  • Lin Wang,
  • Feng Jin,
  • David G. Pfister,
  • Milena Perez Mak,
  • Pedro Rafael Martins de Marchi,
  • Yi Jiang,
  • Haihua Yang,
  • Xiaoye Hu,
  • Tianrun Liu,
  • Dehua Wu,
  • Aditya Shreenivas,
  • Thiago Bueno de Oliveira,
  • Carlos Eduardo Baston Silva,
  • Gustavo Vasconcelos Alves,
  • Xianming Li,
  • Zhifang Yao,
  • Dongmei Lu,
  • Mingxiu Hu,
  • Zhongmin Maxwell Wang,
  • Baiyong Li,
  • Michelle Xia,
  • Xiaozhong Chen,
  • Chaosu Hu,
  • Tingting Xu

摘要

In this phase 3 trial, penpulimab combined with chemotherapy was assessed against a regimen of placebo plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). 291 patients were randomised and allocated in a 1:1 ratio in order to receive penpulimab (n = 144; 200 mg) or placebo (n = 147; 200 mg), plus chemotherapy (cisplatin/carboplatin and gemcitabine) every 3 weeks. Patients followed by maintenance therapy with penpulimab or placebo after 6 cycles. The primary endpoint of this study was progression-free survival (PFS) according to RECIST v1.1, and a significantly longer median PFS in the penpulimab arm versus the placebo arm (9.63 versus 7.00 months; hazard ratio 0.45, 95% CI: 0.33–0.62, P < 0.0001) was demonstrated in this prespecified interim analysis. The key secondary endpoint was the overall survival (OS). However, the OS data were still immature, and the median OS was not achieved (hazard ratio, 0.94; 95% CI: 0.63–1.40). The occurrence of treatment-related adverse events (grade ≥ 3) was 89.0% and 85.9% in two arms, with the most common being reduced the quantity of neutrophil (56.2% vs. 62.0%), reduced the quantity of white blood cell (54.1% vs. 54.9%), and anemia (45.2% vs. 38.7%). In the penpulimab arm, 6 patients (4.1%) experienced immune-related adverse events (grade ≥ 3). Adding penpulimab to chemotherapy led to a notable enhancement in PFS for the first-line R/M NPC treatment, alongside a safety profile that was both manageable and tolerable. ClinicalTrials.gov identifier NCT04974398.